Capivasertib

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

About Capivasertib

Capivasertib is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2023. DrugCentral lists 31 molecular targets, including AKT1, CDC42BPG and AKT3. Recorded indications include Hormone receptor pozitive breast cancer and Human epidermal growth factor 2 negative carcinoma of breast.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Hormone receptor pozitive breast cancer
• Human epidermal growth factor 2 negative carcinoma of breast

Mechanism & targets

Molecular targets (31)

Target	Gene	Action	Activity
RAC-alpha serine/threonine-protein kinase	AKT1	inhibitor	IC50 8.49
Serine/threonine-protein kinase MRCK gamma	CDC42BPG	inhibitor	IC50 8.11
RAC-gamma serine/threonine-protein kinase	AKT3	inhibitor	IC50 8.10
RAC-beta serine/threonine-protein kinase	AKT2	inhibitor	IC50 8.07
Rho-associated protein kinase 2	ROCK2	unknown	IC50 7.25
cAMP-dependent protein kinase catalytic subunit beta	PRKACB	unknown	Kd 6.62
cGMP-dependent protein kinase 1	PRKG1	unknown	Kd 6.53
LIM domain kinase 1	LIMK1	unknown	Kd 6.45
cAMP-dependent protein kinase catalytic subunit alpha	PRKACA	unknown	Kd 6.41
Glycogen synthase kinase-3 beta	GSK3B	inhibitor	IC50 6.38
Rho-associated protein kinase 1	ROCK1	unknown	IC50 6.33
LIM domain kinase 2	LIMK2	unknown	Kd 6.32
Dual specificity protein kinase CLK1	CLK1	unknown	Kd 6.32
Dual specificity protein kinase CLK4	CLK4	unknown	Kd 6.29
Fibroblast growth factor receptor 1	FGFR1	unknown	Kd 6.06
Proline-rich AKT1 substrate 1	AKT1S1	inhibitor	IC50 6.01
Proto-oncogene tyrosine-protein kinase receptor Ret	RET	unknown	Kd 5.96
Serine/threonine-protein kinase N1	PKN1	unknown	Kd 5.80
Protein kinase C alpha type	PRKCA	unknown	Kd 5.76
5'-AMP-activated protein kinase catalytic subunit alpha-1	PRKAA1	unknown	Kd 5.74

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2023-11-16	FDA	—	ASTRAZENECA

ATC classification

ATC code	Therapeutic hierarchy
L01EX27	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: AKT1, ERBB2, ESR1, ESR2, PIK3CD · Testing Required
• FDA label: AKT1, ERBB2, ESR1, ESR2, PIK3CA · Testing Required
• HCSC label: AKT1, ERBB2, ESR1, ESR2, PIK3CA · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hyperglycaemia	909.0
Rash	425.1
Diabetic ketoacidosis	230.2
Death	225.6
Erythema multiforme	209.1
Diarrhoea	204.4
Malignant neoplasm progression	173.4
Disease progression	164.9
Metastases to liver	108.9
Hyperglycaemic hyperosmolar nonketotic syndrome	100.3
Blood glucose increased	58.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Capivasertib is on its molecule page.

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: JDUBGYFRJFOXQC-KRWDZBQOSA-N
• PubChem CID: 25227436

NC1(CCN(CC1)C1=C2C=CN=C2NC=N1)C(=O)N[C@@H](CCO)C1=CC=C(Cl)C=C1

Sources & how this page is made

This page is compiled automatically from public scientific databases and is refreshed when those sources are re-ingested. It is not written or reviewed by a clinician.

• DrugCentral — structures, indications, targets, approvals (CC BY-SA 4.0)
• FDA Orange Book — patents and exclusivity
• FDA Adverse Event Reporting System (FAERS) — adverse-event signals
• PharmGKB / CPIC — pharmacogenomics
• PubChem — chemical identifiers